Australia: QBiotics raises A$85m from offer of shares

QBiotics, a life sciences company developing small molecule anticancer and wound healing pharmaceuticals, has concluded an A$85m (US$64.3m) capital raise from existing shareholders, existing institutional investors, and cornerstone investor TDM Growth Partners. Funding will enable human clinical development of the QBiotics’ anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013. A total…

You must be a HMI Subscriber to view this content.

Subscribe Now »